Eurocor GmbH
Products: Genius MegaFlex, TAXCOR, AMADEUS
Genius MegaFlex
Optimized Pulse Synchronicity
| GENIUS MEGAflex Six-month Registry Data. |
|
| 12.5%.Low binary restenosis despite complex and small vessel lesions. | |
| 180-DAY FOLLOW-UP | |
| Major Cardiac Event Rate |
7.5% |
| Target Lesion Revascularization |
5.6% |
| Target Vessel Failure |
8.5% |
| Subacute Thrombosis |
0.5% |
| AHA/ACC Lesion Class B2&C |
89% |
| Average Lesion Length |
15.2 mm |
| (190 Patients- multi-center study results available upon request) | |
TAXCOR
The clinically most effective Paclitaxel-eluting conorary stenting technology
“Stent Thrombosis is a growing concern”
Clinical Studies show 60% of stent thrombosis lead to a myocardial infarction* - 45% of stent thrombosis lead to death.*
Important TAXCOR Product Features lead to Patient Risk elimination!
TAXCOR eliminates any polymer-induced, late adverse effect potential
TAXCOR eliminates the risk of subacute thrombosis by blood clot formation
TAXCOR fully elutes the entire drug dosage in 20 days
TAXCOR carbon coating protects the patient against sensitivity reactions
TAXCOR shows complete re-endothelialisation
TAXCOR does not require long-term Antiplatelet Therapy.
TAXCOR is fully DLC- Diamond like carbon coated.
